Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1210 (Ravulizumab) in Healthy Japanese Subjects
NCT05288816Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (3 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at Day 298. Started Apr 2016; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05288816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288816.